Augmenix to Present at the Annual Piper Jaffray Healthcare Conference on Wednesday, November 30

WALTHAM, Mass.–(BUSINESS WIRE)–November 17, 2016–

Augmenix, Inc. a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during prostate radiotherapy, today announced that it will present at the Piper Jaffray 28^th Annual Healthcare Conference at the Lotte New York Palace Hotel in New York City on Wednesday, November 30, 2016. John Pedersen, Chief Executive Officer is scheduled to present at 1:10 p.m. Eastern Time.

[aditude-amp id="flyingcarpet" targeting='{"env":"staging","page_type":"article","post_id":2110218,"post_type":"press","post_chan":"none","tags":null,"ai":false,"category":"none","all_categories":"business,","session":"B"}']

About Augmenix, Inc.

Augmenix, Inc. is a privately held company based in the Boston area focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. The company was founded by Incept LLC in 2008 and is funded by several leading venture capital groups. More information about Augmenix can be found at http://www.Augmenix.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161117005459/en/

Augmenix
Eileen Gardner, RN, 781-902-1625
egardner@augmenix.com